Acromegaly - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 87 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acromegaly - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Acromegaly - Pipeline Review, H2 2015', provides an overview of the Acromegaly's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acromegaly, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acromegaly and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acromegaly
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acromegaly and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acromegaly products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acromegaly pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acromegaly
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acromegaly Overview 9
Therapeutics Development 10
Pipeline Products for Acromegaly - Overview 10
Pipeline Products for Acromegaly - Comparative Analysis 11
Acromegaly - Therapeutics under Development by Companies 12
Acromegaly - Therapeutics under Investigation by Universities/Institutes 13
Acromegaly - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Acromegaly - Products under Development by Companies 17
Acromegaly - Products under Investigation by Universities/Institutes 18
Acromegaly - Companies Involved in Therapeutics Development 19
Aegis Therapeutics, LLC 19
Antisense Therapeutics Limited 20
Chiasma, Inc. 21
Crinetics Pharmaceuticals, Inc. 22
DexTech Medical AB 23
Foresee Pharmaceuticals, LLC 24
Ipsen S.A. 25
Isis Pharmaceuticals, Inc. 26
Italfarmaco S.p.A. 27
Novartis AG 28
Peptron, Inc. 29
Sompharmaceuticals S.A. 30
Strongbridge Biopharma plc 31
Acromegaly - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
ATL-1103 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
BIM-23A758 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
COR-005 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
FP-002 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
G-02113 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ISIS-GHRLRx - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ITF-2984 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
L-779976 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
octreotide acetate - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
octreotide acetate - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
octreotide acetate - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
octreotide acetate long acting - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
octreotide acetate SR - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
octreotide SR - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
pasireotide ER - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Somadex - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
SXN-101742 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
SXN-101959 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Acromegaly - Recent Pipeline Updates 66
Acromegaly - Dormant Projects 76
Acromegaly - Discontinued Products 77
Acromegaly - Product Development Milestones 78
Featured News & Press Releases 78
Nov 03, 2015: Strongbridge Biopharma Announces Data Presentation at the Society for Endocrinology BES 2015 Conference 78
Sep 09, 2015: ATL1103 Higher Dose Study-Dosing Commenced 78
Aug 17, 2015: Chiasma Announces FDA Acceptance For Filing of New Drug Application for Octreotide Capsules in Acromegaly 79
Aug 10, 2015: ANP Licensing Partner for ATL1103 Cortendo Files Prospectus 80
Jun 15, 2015: Chiasma Submits New Drug Application to U.S. FDA for Octreotide Capsules in Acromegaly 80
Apr 16, 2015: ATL1103 - New European Patent Application Allowance 81
Mar 06, 2015: ATL1103 Phase II Trial Data to be presented at ENDO 2015 81
Mar 05, 2015: ATL1103 Higher Dose Study to Support Phase III to Commence 82
Mar 05, 2015: Chiasma Announces New Data for Investigational Octreotide Capsules 82
Feb 09, 2015: Newly Published Phase III Study Results Show Positive Outcomes for Octreotide Capsules in People with Acromegaly 84
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 86
Disclaimer 87

List of Tables

Number of Products under Development for Acromegaly, H2 2015 10
Number of Products under Development for Acromegaly - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Number of Products under Investigation by Universities/Institutes, H2 2015 13
Comparative Analysis by Late Stage Development, H2 2015 14
Comparative Analysis by Clinical Stage Development, H2 2015 15
Comparative Analysis by Early Stage Development, H2 2015 16
Products under Development by Companies, H2 2015 17
Products under Investigation by Universities/Institutes, H2 2015 18
Acromegaly - Pipeline by Aegis Therapeutics, LLC, H2 2015 19
Acromegaly - Pipeline by Antisense Therapeutics Limited, H2 2015 20
Acromegaly - Pipeline by Chiasma, Inc., H2 2015 21
Acromegaly - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2015 22
Acromegaly - Pipeline by DexTech Medical AB, H2 2015 23
Acromegaly - Pipeline by Foresee Pharmaceuticals, LLC, H2 2015 24
Acromegaly - Pipeline by Ipsen S.A., H2 2015 25
Acromegaly - Pipeline by Isis Pharmaceuticals, Inc., H2 2015 26
Acromegaly - Pipeline by Italfarmaco S.p.A., H2 2015 27
Acromegaly - Pipeline by Novartis AG, H2 2015 28
Acromegaly - Pipeline by Peptron, Inc., H2 2015 29
Acromegaly - Pipeline by Sompharmaceuticals S.A., H2 2015 30
Acromegaly - Pipeline by Strongbridge Biopharma plc , H2 2015 31
Assessment by Monotherapy Products, H2 2015 32
Number of Products by Stage and Target, H2 2015 34
Number of Products by Stage and Mechanism of Action, H2 2015 36
Number of Products by Stage and Route of Administration, H2 2015 38
Number of Products by Stage and Molecule Type, H2 2015 40
Acromegaly Therapeutics - Recent Pipeline Updates, H2 2015 66
Acromegaly - Dormant Projects, H2 2015 76
Acromegaly - Discontinued Products, H2 2015 77